LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 26, 2021 at 12:40 pm
Share
LanZhou Foci Pharmaceutical Co.,Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 664.17 million compared to CNY 502.3 million a year ago. Revenue was CNY 664.17 million compared to CNY 502.3 million a year ago. Net income was CNY 73.73 million compared to CNY 108.14 million a year ago. Basic earnings per share from continuing operations was CNY 0.1444 compared to CNY 0.2118 a year ago. Diluted earnings per share from continuing operations was CNY 0.1444 compared to CNY 0.2118 a year ago.
LanZhou Foci Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs and large health products. The Companyâs main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The Company distributes its products under the brand names Foci, Baolu and Mianshan. The Company is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The Company distributes its products in domestic market and to overseas markets.
LANZHOU FOCI PHARMACEUTICAL CO.,LTD. 
